This mid-cap multibagger Pharma company signs MOA with IIT Kanpur for novel gene therapy assets! This mid-cap multibagger Pharma company signs MOA with IIT Kanpur for novel gene therapy assets! The company delivered exceptional returns of 251 per cent over the past 3 years. Siddharth Mane / Monday, June 19, 2023 / Article rating: 3.8 The company delivered exceptional returns of 251 per cent over the past 3 years, while over the past 5 years, it provided remarkable returns of 242 per cent.